Metropolis Healthcare Launches Scientifically Curated GLP-1 Monitoring Test Packages

The GLP-1 monitoring panels measure critical metabolic and nutritional biomarkers to help clinicians track treatment effects and identify early risks in patients using GLP-1 therapies.

Metropolis Healthcare has introduced specialized GLP-1 monitoring test packages designed to track metabolic changes, nutritional markers, and potential therapy-associated risks among individuals using GLP-1-based weight-management or diabetes regimens.

The test panels are curated to evaluate key biomarkers affected by GLP-1 receptor agonists, including parameters linked to glycaemic control, pancreatic health, liver function, vitamin levels and metabolic status.

The packages support clinicians in identifying early deviations that may require adjustment of therapy or nutritional supplementation.

Announcing the launch, leadership from Metropolis Healthcare highlighted that rising adoption of GLP-1 therapies has increased the need for structured monitoring frameworks to ensure safe and effective long-term use.

Dr Deepak Sanghavi, Deputy Chief Operating Officer, Metropolis Healthcare, noted, “GLP-1 therapies influence multiple metabolic pathways. Our monitoring panels are designed to give clinicians a consolidated view of essential biomarkers that guide ongoing treatment decisions.”

The GLP-1 monitoring menu includes tests measuring HbA1c, fasting glucose, lipid profile, renal and hepatic markers, pancreatic enzymes and micronutrient indicators such as vitamin B12 and vitamin D. Each package is structured to support baseline assessment, periodic tracking and post-therapy evaluation.

Experts associated with the programme mentioned that structured diagnostic monitoring is increasingly recommended for patients using GLP-1 analogues, particularly as demand grows for chronic weight-management therapies and metabolic disease interventions.

The initiative aligns with the broader move toward personalized metabolic care, offering evidence-driven diagnostics to support safer adoption of GLP-1-based treatments across clinical and wellness settings.

Metropolis Healthcare has been expanding its specialized diagnostics portfolio, most recently introducing scientifically curated GLP-1 monitoring test packages designed to track metabolic changes, nutritional markers and therapy-associated risks for individuals using GLP-1 based weight-management and diabetes treatments.

Stay tuned for more such updates on Digital Health News